Overview

Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Collaborators:
Takeda
Takeda Bio Development Center, Ltd
Treatments:
Imatinib Mesylate
Motesanib diphosphate
Niacinamide